NSE: ALKEM · 13 November 2026
- Alkem Laboratories Ltd. (ALKEM) dropped 3.55% today, closing at ₹5,114.00 after moving within a day's range of ₹5,103.50 and ₹5,300.50.
- Alkem Laboratories announced its standalone and consolidated financial results for the second quarter ended September 30, 2026. Total revenue from operations reached ₹45,520 million, reflecting a 13.8% YoY growth, while EBITDA stood at ₹10,252 million with a margin of 22.5%. Net profit after non-controlling interest was reported at ₹6,753 million.
- Trading volume was 2.70 times the 20-day average daily volume.
Why is Alkem Laboratories share price falling on 13 November 2026?
Alkem Laboratories Ltd. (ALKEM) dropped 3.55% today, closing at ₹5,114.00 after moving within a day's range of ₹5,103.50 and ₹5,300.50.
The broader market and sector indices also experienced downward pressure during the session, with the Nifty falling 0.61% and the Nifty Pharma sector benchmark declining 0.49%. Alkem's steeper 3.55% drop reflects intensified selling pressure compared to its healthcare peers, compounding recent weakness that includes a 5-day return of -1.46% and a 20-day return of -1.67%.
Company disclosures from earlier in the week provide fundamental backdrop following the release of its second-quarter financial results for the period ended September 30, 2026, which reported total revenue from operations at ₹45,520 million and net profit at ₹6,753 million. While these operational updates and leadership changes—such as the appointment of Dr.
4.07 lakh shares traded by 13 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.51 lakh shares (2.70 times). The five-day average daily volume was 2.95 lakh shares. Separately, the NSE report for 13 November 2026 showed 1.87 lakh shares delivered, representing 45.96% of that day’s traded volume. The same report recorded 55,459 trades.
The stock declined 3.55% on heavy volume that reached 2.70 times its 20-day average, extending recent underperformance without a direct same-day negative news catalyst. The move coincides with broader sector softness and follows recent quarterly financial disclosures.
Latest Company Developments
Alkem Laboratories announced its standalone and consolidated financial results for the second quarter ended September 30, 2026. Total revenue from operations reached ₹45,520 million, reflecting a 13.8% YoY growth, while EBITDA stood at ₹10,252 million with a margin of 22.5%. Net profit after non-controlling interest was reported at ₹6,753 million.
Quarterly earnings reports directly impact valuation, margin assessments, and investor expectations regarding core pharmaceutical and international execution.
The company completed the incorporation of a subsidiary in the form of a Joint Venture named 'Alkem Pharma Company' in the Kingdom of Saudi Arabia. Alkem subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, market, and distribute pharmaceutical and nutraceutical products.
This strategic expansion broadens the company's geographic footprint and market reach into the Middle East pharmaceutical market.
The Board of Directors approved the appointment of Dr. Amrut Naik as the Chief Executive Officer and Key Managerial Personnel of the company, effective November 11, 2026. Dr. Naik brings over 26 years of global pharmaceutical experience spanning branded formulations, generics, APIs, and biologics.
Top-level leadership changes influence strategic execution, operational priorities, and long-term business transformation initiatives.
Appointment of Mr Gopal Kothari as Chief Financial Officer of the Company w.e.f. December 02, 2026.
Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.
The filing reported 29 MF/UTI holders.
Research & Brokerage Views
Maintained a Neutral rating with a target price of ₹5,890 following preceding quarterly outperformance, balancing domestic momentum against US pricing pressures.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and integration of newly acquired Occlutech and Enzene operational performance
- Remediation progress regarding regulatory status updates at the Daman formulation facility
- Performance trends in chronic versus acute domestic therapeutic portfolios tracked via IQVIA data
- Market reaction and trading volume persistence around the ₹5,100 support level
Other Dated Coverage
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 2.68% | 12 November 2026 — 12 November 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026 — 23 October 2026
- Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.03% | 22 October 2026 — 22 October 2026
More Alkem Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Alkem Laboratories company news?
Alkem Laboratories announced its standalone and consolidated financial results for the second quarter ended September 30, 2026. Total revenue from operations reached ₹45,520 million, reflecting a 13.8% YoY growth, while EBITDA stood at ₹10,252 million with a margin of 22.5%. Net profit after non-controlling interest was reported at ₹6,753 million.
How strong was Alkem Laboratories’s trading volume?
4.07 lakh shares traded, 2.70 times the 20-day average daily volume. The price and volume data are dated 13 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.